+353-1-416-8900REST OF WORLD
+44-20-3973-8888REST OF WORLD
1-917-300-0470EAST COAST U.S
1-800-526-8630U.S. (TOLL FREE)

Results for tag: "Factor VIII"

From
From
From
From
Hemophilia Market Report 2026 - Product Thumbnail Image

Hemophilia Market Report 2026

  • Report
  • February 2026
  • 250 Pages
  • Global
From
Acquired Hemophilia Treatment Market Report 2026 - Product Thumbnail Image

Acquired Hemophilia Treatment Market Report 2026

  • Report
  • February 2026
  • 250 Pages
  • Global
From
Coagulation Factor Deficiency Market Report 2026 - Product Thumbnail Image

Coagulation Factor Deficiency Market Report 2026

  • Report
  • February 2026
  • 250 Pages
  • Global
From
From
Hemophilia Drugs - Global Strategic Business Report - Product Thumbnail Image

Hemophilia Drugs - Global Strategic Business Report

  • Report
  • May 2026
  • 182 Pages
  • Global
From
From
Rare Hemophilia Factors - Global Strategic Business Report - Product Thumbnail Image

Rare Hemophilia Factors - Global Strategic Business Report

  • Report
  • May 2026
  • 132 Pages
  • Global
From
Synthetic Blood Substitutes and Blood Products Market Report 2026 - Product Thumbnail Image

Synthetic Blood Substitutes and Blood Products Market Report 2026

  • Report
  • February 2026
  • 250 Pages
  • Global
From
Hemostasis Market Report and Forecast 2025-2034 - Product Thumbnail Image

Hemostasis Market Report and Forecast 2025-2034

  • Report
  • June 2025
  • 400 Pages
  • Global
From
From
Hemophilia Drug Pipeline Analysis Report 2025 - Product Thumbnail Image

Hemophilia Drug Pipeline Analysis Report 2025

  • Drug Pipelines
  • June 2025
  • 200 Pages
  • Global
From
Hemophilia A Epidemiology Forecast 2025-2034 - Product Thumbnail Image

Hemophilia A Epidemiology Forecast 2025-2034

  • Report
  • June 2025
  • 150 Pages
  • Global
From
From
Hemophilia Market - Forecast from 2026 to 2031 - Product Thumbnail Image

Hemophilia Market - Forecast from 2026 to 2031

  • Report
  • January 2026
  • 149 Pages
  • Global
From
Loading Indicator

The Factor VIII market is a segment of the hematological drugs market, which includes drugs used to treat blood-related disorders. Factor VIII is a protein that helps blood to clot, and is used to treat hemophilia A, a genetic disorder that impairs the body's ability to form blood clots. Factor VIII is typically administered intravenously, and is available in both recombinant and plasma-derived forms. The Factor VIII market is highly competitive, with a number of companies offering products. These include Novo Nordisk, Pfizer, Bayer, CSL Behring, and Shire. Additionally, there are several smaller companies that offer Factor VIII products, such as Octapharma, Kedrion, and Biotest. Show Less Read more